1. Signaling Pathways
  2. PI3K/Akt/mTOR
  3. mTOR

mTOR (哺乳动物雷帕霉素靶蛋白)

Mammalian target of Rapamycin

mTOR(哺乳动物雷帕霉素靶蛋白)是一种由人类 mTOR 基因编码的蛋白质。mTOR 是一种丝氨酸/苏氨酸蛋白激酶,可调节细胞生长、细胞增殖、细胞运动、细胞存活、蛋白质合成和转录。mTOR 属于磷脂酰肌醇 3-激酶相关激酶蛋白家族。mTOR 整合上游通路的输入,包括生长因子和氨基酸。mTOR 还能感知细胞营养、氧气和能量水平。mTOR 通路在人类疾病中失调,例如糖尿病、肥胖症、抑郁症和某些癌症。雷帕霉素通过与其细胞内受体 FKBP12 结合来抑制 mTOR。FKBP12-雷帕霉素复合物直接与 mTOR 的 FKBP12-雷帕霉素结合 (FRB) 域结合,从而抑制其活性。

mTOR (mammalian target of Rapamycin) is a protein that in humans is encoded by the mTOR gene. mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family. mTOR integrates the input from upstream pathways, including growth factors and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-153120
    PI3K/mTOR Inhibitor-13 Inhibitor
    PI3K/mTOR Inhibitor-13 是一种具有口服活性的磷酸肌醇 3-激酶 (PI3K) 和 mTOR 激酶双重抑制剂。PI3K/mTOR Inhibitor-13 在性疾病、实体瘤和特发性肺纤维化 (IPF) 中有潜在应用。
    PI3K/mTOR Inhibitor-13
  • HY-168919
    KRASG12C IN-16 Inhibitor
    KRASG12C IN-16 (Compound SK-17) 是一种选择性、共价且具有口服活性的 KRASG12C 抑制剂。KRASG12C IN-16 可诱导细胞凋亡 (Apoptosis)。KRASG12C IN-16 可有效阻止 MAPKPI3K/mTOR 信号通路的激活。KRASG12C IN-16 显示出对胰腺癌的抗肿瘤活性。
    KRASG12C IN-16
  • HY-162023
    mTOR inhibitor-10 Inhibitor
    mTOR inhibitor-10 (Compound 9c) 是 mTOR 的选择性抑制剂。mTOR inhibitor-10 抑制 mTORPI3K-αIC50分别为 0.7 和 825 nM。mTOR inhibitor-10 抑制 LNCaP 增殖,IC50为 87 nM。
    mTOR inhibitor-10
  • HY-N0022R
    Isoacteoside (Standard)

    异麦角甾苷 (Standard)

    Inhibitor
    Isoacteoside (Standard) 是 Isoacteoside 的分析标准品。本产品用于研究及分析应用。Isoacteoside是天然产物,能显著地抑制糖基化终产物的形成。Isoacteoside standard 调节 AKT/PI3K/m-TOR/NF-κB 信号通路,诱导 OVCAR-3 细胞凋亡 (apoptosis)。Isoacteoside standard 具有抗肿瘤、抗炎、抗肥胖和神经保护作用。
    Isoacteoside (Standard)
  • HY-15900R
    Voxtalisib (Standard) Inhibitor
    Voxtalisib (Standard) 是 Voxtalisib 的分析标准品。本产品用于研究及分析应用。Voxtalisib (XL765) 是一种有效的 PI3K 抑制剂,抑制p110αp110βp110γp110δIC50 分别为 39, 113, 9 和 43 nM,也抑制 DNA-PK (IC50=150 nM) 和 mTOR (IC50
    Voxtalisib (Standard)
  • HY-15247R
    Vistusertib (Standard)

    奥西替尼杂质1 (AZD2014) (标准品)

    Inhibitor
    Vistusertib (Standard) 是 Vistusertib 的分析标准品。本产品用于研究及分析应用。Vistusertib (AZD2014) 是一种ATP竞争性的 mTOR 抑制剂,IC50 为 2.81 nM。AZD2014 抑制 mTORC1mTORC2 复合物。
    Vistusertib (Standard)
  • HY-W114419
    Bisphenol C Inhibitor ≥98.0%
    Bisphenol C 是雌激素受体 α (ERα) 激动剂和 ERβ 拮抗剂,对 ERαIC50 值为 2.65 nM,对 ERβIC50 值为 1.94 nM。Bisphenol C 是制造聚碳酸酯等聚酯聚合物的原料,广泛用于水瓶、食品包装、纺织品等日常用品中。
    Bisphenol C
  • HY-100542R
    D-α-Hydroxyglutaric acid disodium (Standard)

    (R)-2-羟基戊二酸二钠盐 (Standard)

    Inhibitor
    D-α-Hydroxyglutaric acid (disodium) (Standard)是 D-α-Hydroxyglutaric acid (disodium) 的分析标准品。本产品用于研究及分析应用。D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) 是神经代谢疾病 D-2-羟基戊二酸尿症中积累的主要代谢产物。D-α-Hydroxyglutaric acid disodium 是 α-酮戊二酸 (α-KG) 的弱竞争拮抗剂,可抑制多种 α-KG 依赖性双加氧酶 (dioxygenases),Ki 为 10.87 mM。D-α-Hydroxyglutaric acid disodium 可增加活性氧 (ROS) 的产生。D-α-Hydroxyglutaric acid disodium 还可结合并抑制 ATP 合酶并抑制 mTOR 信号传导。
    D-α-Hydroxyglutaric acid disodium (Standard)
  • HY-W781875
    Sirolimus isomer C
    Sirolimus isomer C 是 Rapamycin (Sirolimus) (HY-10219) 的杂质。
    Sirolimus isomer C
  • HY-15174R
    Dactolisib Tosylate (Standard) Inhibitor
    Dactolisib (Tosylate) (Standard) 是 Dactolisib (Tosylate) 的分析标准品。本产品用于研究及分析应用。Dactolisib Tosylate (BEZ235 Tosylate) 是PI3KmTOR的双重激酶抑制剂,对PI3Kα, β, γ, δ 的IC50值分别为4, 75, 7, 5 nM。Dactolisib Tosylate (BEZ235 Tosylate) 抑制 mTORC
    Dactolisib Tosylate (Standard)
  • HY-171229
    1-Acetyl-DHAP Substrate
    1-Acetyl-DHA (Compound 7) 是磷酸三酯酶同源蛋白 (PHP) 的底物,可被 PHP 水解,kcat/km 值为 100 M-1s-1。1-Acetyl-DHA 的水平受 mTORC1 调控,与核醋酸水平呈负相关。1-Acetyl-DHA 在细胞代谢与组蛋白乙酰化调控中发挥重要作用。
    1-Acetyl-DHAP
  • HY-164385
    NSC126405 Inhibitor
    NSC126405 是一种 mTOR-DEPTOR 抑制剂,能够结合 DEPTOR,阻止 mTOR 与 DEPTOR 的结合,并诱导多发性骨髓瘤 (MM) 的细胞毒性。NSC126405 可用于癌症研究。
    NSC126405
  • HY-N15267
    Ovalitenone Inhibitor
    Ovalitenone 是一种可从植物 Millettia peguensis 中分离得到的一种黄酮类化合物。Ovalitenone 对肺癌 H460 和 A549 细胞没有细胞毒性作用,但显著抑制了非锚定依赖性生长、类似 CSC 的表型、集落形成以及癌细胞迁移和侵袭的能力。Ovalitenone 能够显著降低 N-钙黏蛋白、snail 和 slug 的水平,同时增加 E-钙黏蛋白,抑制 EMT 途径。Ovalitenone 还抑制了焦附激酶 (FAK)、ATP 依赖性酪氨酸激酶 (AKT)、哺乳动物雷帕霉素靶蛋白 (mTOR) 和细胞分裂周期 42 (Cdc42) 的调控信号通路。
    Ovalitenone
  • HY-N0914R
    Ajugol (Standard)

    益母草苷 (Standard)

    Inhibitor
    Ajugol (Standard) 是 Ajugol (HY-N0914) 的分析标准品。本产品用于研究及分析应用。Ajugol 是一种从传统中药益母草 (Leonurus japonicus) 中发现的具有口服活性的环烯醚糖苷。Ajugol 是一种自噬 (autophagy) 激活剂。Ajugol 可激活 TFEB 介导的自噬和溶酶体生物合成。Ajugol 还具有抗炎和抗原虫活性作用。Ajugol 在哮喘、非酒精性脂肪肝 (NAFLD)、骨关节炎的疾病研究中具有很大潜力。
    Ajugol (Standard)
  • HY-155211
    mTOR inhibitor-13 Inhibitor
    mTOR inhibitor-13(化合物 9g)是一种芳基脲基化合物,是一种有效的选择性 mTOR 抑制剂,IC50 为 0.29 nM。mTOR inhibitor-13 还抑制 PI3K-αIC50 为 119 nM。
    mTOR inhibitor-13
  • HY-164384
    DFX117 Inhibitor
    DFX117 是口服有效的 PI3Kα 和 c-Met 酪氨酸激酶 (c-Met) 选择性抑制剂。DFX117 抑制 PI3K/Akt/mTOR 通路,抑制 NCI-H1975、NCI-H1993 和 HCC827 的增殖,IC50 为 0.02-0.08 µM。DFX117 在 G0/G1 期阻滞细胞周期,诱导 A549 和 NCI-H1975 细胞凋亡 (apoptosis)。DFX117 在小鼠中表现出抗肿瘤活性。i
    DFX117
  • HY-13610AR
    N1,N11-Diethylnorspermine tetrahydrochloride (Standard) Inhibitor
    N1,N11-Diethylnorspermine (tetrahydrochloride) (Standard) 是 N1,N11-Diethylnorspermine (tetrahydrochloride) 的分析标准品。本产品用于研究及分析应用。N1, N11-Diethylnorspermine tetrahydrochloride (DENSPM tetrahydrochloride) 是一种有效的抗癌剂。N1, N11-Diethylnorspermine tetrahydrochlorid
    N1,N11-Diethylnorspermine tetrahydrochloride (Standard)
  • HY-162024
    mTOR inhibitor-16 Inhibitor
    mTOR inhibitor-16 (Compound 9f) 是 mTOR 的选择性抑制剂。mTOR inhibitor-10 抑制 mTORPI3K-αIC50 分别为 1.25 和 82 nM。mTOR inhibitor-10 抑制 LNCaP 细胞增殖,IC50 为 140 nM。
    mTOR inhibitor-16
  • HY-13246R
    Apitolisib (Standard) Inhibitor
    Apitolisib (Standard) 是 Apitolisib 的分析标准品。本产品用于研究及分析应用。Apitolisib (GDC-0980; GNE 390; RG 7422) 是一种口服有效的 PI3KmTOR (TORC1/2) 激酶抑制剂,抑制 PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ 的活性,IC50 值为 5 nM/27 nM/7 nM/14 nM。 抑制mTORKi 为 17 nM。
    Apitolisib (Standard)
  • HY-116191
    WJD008 Inhibitor
    WJD008 是一种强效的双重磷脂酰肌醇 3-激酶 (PI3K)/哺乳动物雷帕霉素靶点 (mTOR) 抑制剂,对肿瘤细胞和带有 PIK3CA 突变的转化细胞表现出抗增殖和抗克隆生成的作用。WJD008 抑制 PI3K αmTOR 的激酶活性,并消除了类胰岛素生长因子-I 激活的 PI3K-Akt-mTOR 信号通路。WJD008 有望用于癌症的研究。
    WJD008
目录号 产品名 / 同用名 应用 反应物种

The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and survival[1]. mTOR is the catalytic subunit of two distinct complexes called mTORC1 and mTORC2. mTORC1 comprises DEPTOR, PRAS40, RAPTOR, mLST8, mTOR, whereas mTORC2 comprises DEPTOR, mLST8, PROTOR, RICTOR, mSIN1, mTOR[2]. Rapamycin binds to FKBP12 and inhibits mTORC1 by disrupting the interaction between mTOR and RAPTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1 and TFEB. mTORC1 promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1, and regulates glycolysis through HIF-1α. It promotes de novo lipid synthesis through the SREBP transcription factors. mTORC2 inhibits FOXO1,3 through SGK and Akt, which can lead to increased longevity. The complex also regulates actin cytoskeleton assembly through PKC and Rho kinase[3]

 

Growth factors: Growth factors can signal to mTORC1 through both PI3K-Akt and Ras-Raf-MEK-ERK axis. For example, ERK and RSK phosphorylate TSC2, and inhibit it.

 

Insulin Receptor: The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of these proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt and triggers the Akt-dependent multisite phosphorylation of TSC2. TSC is a heterotrimeric complex comprised of TSC1, TSC2, and TBC1D7, and functions as a GTPase activating protein (GAP) for the small GTPase Rheb, which directly binds and activates mTORC1. mTORC2 primarily functions as an effector of insulin/PI3K signaling. 

 

Wnt: The Wnt pathway activates mTORC1. Glycogen synthase kinase 3β (GSK-3β) acts as a negative regulator of mTORC1 by phosphorylating TSC2. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1[4].

 

Amino acids: mTORC1 senses both lysosomal and cytosolic amino acids through distinct mechanisms. Amino acids induce the movement of mTORC1 to lysosomal membranes, where the Rag proteins reside. A complex named Ragulator, interact with the Rag GTPases, recruits them to lysosomes through a mechanism dependent on the lysosomal v-ATPase, and is essential for mTORC1 activation. In turn, lysosomal recruitment enables mTORC1 to interact with GTP-bound RHEB, the end point of growth factor. Cytosolic leucine and arginine signal to mTORC1 through a distinct pathway comprised of the GATOR1 and GATOR2 complexes.    

 

Stresses: mTORC1 responds to intracellular and environmental stresses that are incompatible with growth such as low ATP levels, hypoxia, or DNA damage. A reduction in cellular energy charge, for example during glucose deprivation, activates the stress responsive metabolic regulator AMPK, which inhibits mTORC1 both indirectly, through phosphorylation and activation of TSC2, as well as directly through the phosphorylation of RAPTOR. Sestrin1/2 are two transcriptional targets of p53 that are implicated in the DNA damage response, and they potently activate AMPK, thus mediating the p53-dependent suppression of mTOR activity upon DNA damage. During hypoxia, mitochondrial respiration is impaired, leading to low ATP levels and activation of AMPK. Hypoxia also affects mTORC1 in AMPK-independent ways by inducing the expression of REDD1, the protein products of which then suppress mTORC1 by promoting the assembly of TSC1-TSC2[2].

 

Reference:

[1]. Laplante M, et al.mTOR signaling at a glance.J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94. 
[2]. Zoncu R, et al. mTOR: from growth signal integration to cancer, diabetes and ageing.Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. 
[3]. Johnson SC, et al. mTOR is a key modulator of ageing and age-related disease.Nature. 2013 Jan 17;493(7432):338-45.
[4]. Shimobayashi M, et al. Making new contacts: the mTOR network in metabolism and signalling crosstalk.Nat Rev Mol Cell Biol. 2014 Mar;15(3):155-62.

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.